Literature DB >> 21777393

Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties.

Hwangseo Park1, Suk-Kyeong Jung, Keum R Yu, Ju H Kim, Yong-Sam Kim, Jeong H Ko, Byoung C Park, Seung J Kim.   

Abstract

Despite a series of persuasive experimental evidence for the involvement of eyes absent protein tyrosine phosphatases in various human cancers, no small-molecule inhibitor has been reported so far. We have identified seven novel inhibitors of eyes absent homologue 2 (Eya2) with IC(50) values ranging from 1 to 70 μm by the virtual screening with docking simulations and enzyme inhibition assay. Atomic charges of the active-site Mg(2+) ion complex are calculated to enhance the accuracy of docking simulations. The newly discovered inhibitors are structurally diverse and have various chelating groups for the Mg(2+) ion. The interactions with the amino acid residues responsible for the stabilizations of the inhibitors in the active site of Eya2 are addressed in detail.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777393     DOI: 10.1111/j.1747-0285.2011.01192.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  10 in total

1.  EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Authors:  Tyler P Robin; Anna Smith; Erin McKinsey; Lisa Reaves; Paul Jedlicka; Heide L Ford
Journal:  Mol Cancer Res       Date:  2012-06-20       Impact factor: 5.852

2.  Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.

Authors:  Aaron B Krueger; David J Drasin; Wendy A Lea; Aaron N Patrick; Samarjit Patnaik; Donald S Backos; Christopher J Matheson; Xin Hu; Elena Barnaeva; Michael J Holliday; Melanie A Blevins; Tyler P Robin; Elan Z Eisenmesser; Marc Ferrer; Anton Simeonov; Noel Southall; Philip Reigan; Juan Marugan; Heide L Ford; Rui Zhao
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 3.  The Eyes Absent proteins in development and disease.

Authors:  Emmanuel Tadjuidje; Rashmi S Hegde
Journal:  Cell Mol Life Sci       Date:  2012-09-13       Impact factor: 9.261

4.  Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Authors:  Aaron B Krueger; Seameen J Dehdashti; Noel Southall; Juan J Marugan; Marc Ferrer; Xueni Li; Heide L Ford; Wei Zheng; Rui Zhao
Journal:  J Biomol Screen       Date:  2012-07-20

Review 5.  The SIX1-EYA transcriptional complex as a therapeutic target in cancer.

Authors:  Melanie A Blevins; Christina G Towers; Aaron N Patrick; Rui Zhao; Heide L Ford
Journal:  Expert Opin Ther Targets       Date:  2015-01-02       Impact factor: 6.902

Review 6.  The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target.

Authors:  Melanie A Blevins; Mingxia Huang; Rui Zhao
Journal:  Mol Cancer Ther       Date:  2017-06       Impact factor: 6.261

Review 7.  The Eya phosphatase: Its unique role in cancer.

Authors:  Hengbo Zhou; Lingdi Zhang; Rebecca L Vartuli; Heide L Ford; Rui Zhao
Journal:  Int J Biochem Cell Biol       Date:  2017-09-05       Impact factor: 5.085

8.  The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.

Authors:  Emmanuel Tadjuidje; Tim Sen Wang; Ram Naresh Pandey; Saulius Sumanas; Richard A Lang; Rashmi S Hegde
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  Switchable highly regioselective synthesis of 3,4-dihydroquinoxalin-2(1H)ones from o-phenylenediamines and aroylpyruvates.

Authors:  Juraj Dobiaš; Marek Ondruš; Gabriela Addová; Andrej Boháč
Journal:  Beilstein J Org Chem       Date:  2017-07-10       Impact factor: 2.883

Review 10.  The retinal determination gene network: from developmental regulator to cancer therapeutic target.

Authors:  Deguang Kong; Yu Liu; Qian Liu; Na Han; Cuntai Zhang; Richard G Pestell; Kongming Wu; Gaosong Wu
Journal:  Oncotarget       Date:  2016-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.